INTRODUCTION
The first case of acquired immunodeficiency syndrome (AIDS) was reported in June 1981 (22) . As of August 1987, more than 40 ,000 cases of AIDS have been reported in the United States according to the Centers for Disease Control (CDC) (30) . More than half of these patients have died, and the remainder will probably die within a couple of years unless effective treatment is developed. The cause of this deadly disease is a human retrovirus now known as human immunodeficiency virus type 1 (HIV). This virus was discovered by Montagnier's group in 1983, using electron microscopy, reverse transcriptase assay of culture supernatant fluid, immunofluorescence, and radioimmunoprecipitation (7) . These results were later confirmed, and the virus was further characterized by Gallo's group in 1984 (47, 98, 107, 109) . HIV is now known to infect preferentially CD4 lymphocytes (T-helper cells) which results in severe immunologic impairment, leading to opportunistic infections, cancer, and death (62, 68, 126, 128) . HIV can also infect macrophages and possibly other cell types in the central nervous system, which may lead to severe dementia (49, 69, 70) . On the other hand, having integrated into the deoxyribonucleic acid (DNA) of host cells, the virus can remain latent for years without causing any signs or symptoms.
Nevertheless, 76% of individuals who have been infected at least 7 Exposure to body fluids such as semen, blood, and cervical secretions appears necessary for transmission (25) . Consequently, most AIDS patients intially were sexually active homosexual men, blood transfusion recipients, hemo-* Corresponding author. philia patients, intravenous drug abusers who shared needles, and infants of infected mothers (25) . However, as the prevalence of HIV infection increases, the general population will become at greater risk primarily through heterosexual transmission, as apparently has been the case in Africa (99) .
Fear that HIV infection could be transmitted by blood transfusion prompted the development of a diagnostic routine screening test for HIV antibodies in the serum of blood donors who do not recognize or admit their own risk of infection (107) . In addition to protecting the blood supply, the test has been useful for other prevention efforts in high-risk groups and in making the diagnosis of AIDS, because the disease has many different clinical presentations.
The CDC now estimates that 1.5 million Americans are infected and predicts that there will be 324,000 AIDS cases in the United States by the end of 1991 (119) . Moreover, another retrovirus, named HIV-2, which also causes AIDS, has recently been reported in Africa (33) . The existence of an additional pathogenic human retrovirus could increase the CDC estimates. The need for clinical laboratories to develop expertise in the diagnostic testing for HIV will only become greater. In this review, we discuss the principles, procedures, and merits of the different HIV detection assays and address the biohazards of HIV (29) . Less commonly used as a supplemental test is the indirect immunofluorescence assay (IFA) or radioimmunoprecipitation assay (RIPA). Positive reactivity by one of these assays confirms the presence of HIV antibody, which is indicative of past exposure to HIV proteins and presumably current HIV infection. However, it should be noted that, while these tests are used to confirm positive EIA results, they are not necessarily more sensitive or specific than the EIA, because they are technically difficult and subjective in interpretation and the procedures and reagents vary considerably in different laboratories (17) . In fact, of these supplemental assays, only one commercial Western blot kit (E. I. du Pont de Nemours & Co., Inc., Wilmington, Del.) has been licensed as of July 1987.
With this in mind, we now describe the methods and clinical utility of these assays for HIV antibody detection.
EIA
The EIA test for HIV antibody was developed in the research laboratory soon after HIV was discovered to be the causative agent of AIDS. Nearly all commercial kits use the same method, in which partially purified viral antigens derived from whole disrupted virus in cell culture are bound to polystyrene beads or to plastic microtiter wells. The serum or plasma sample is incubated with the fixed antigens for 30 min to 2 h and then washed. If any immunoglobulin G (IgG) antibody attaches to the bead or well, it will be detected when an anti-IgG antibody is added. Typically, the anti-IgG antibody is labeled with an enzyme (i.e., alkaline phosphatase, horseradish peroxidase) so that, after any unbound antibody is washed away, an enzymatic reaction will produce a color proportional to the amount of human IgG present when a substrate is added. Some EIA kits use a mixture of antibodies to the heavy chains and light chains of human immunoglobulin so that IgM antibodies to HIV may also be detected. Positive and negative controls are run simultaneously to determine the absorbance level or cutoff value above which a positive reaction is defined. Most EIA kits are automated and take <4 h to perform.
Initially, a single sample from a serum or plasma specimen is tested. In patients who have recently been transfused with blood or fluid expanders, a pretransfusion specimen should be used for testing to avoid dilution of HIV antibody to undetectable levels (28) . If the test result is positive, two samples from the initial specimen are typically tested. If at least two of three samples show positive reactivity, the specimen is considered to be repeatedly reactive and a supplemental assay such as a Western blot assay should be performed (81) . No repeatedly reactive units of blood should be used for transfusion regardless of the supplemental test result (23) , even though these donors are unlikely to be infected (19, 39) . Patients or blood units that are nonreactive in at least two of three ETAs are considered to be noninfectious, and supplemental testing is not necessary unless the individual is in a high-risk group for HIV infection.
The sensitivity and specificity of the commercial ETAs are quite good if one uses the Western blot as the "gold" standard. In a comparison study of six different commercial EIA kits, the sensitivity of the assays ranged from 98.1 to 100.0% based on 163 Western blot-positive individuals (101) .
In testing 4,999 Western blot-negative blood donors, 0.06 to 1.3% were initially reactive and 0.0 to 0.42% were repeatedly reactive, giving a specificity of 99.6 to 100.0%. However, the predictive value of a positive test was highly dependent on the prevalence of HIV infection in the population tested. In AIDS and ARC patients, the predictive value of a positive test was 100% for all six EIA kits, but ranged from 5 to 100% in the blood donor group. In another study, the predictive value of a negative EIA test ranged from 99.99% in the general population to as low as 76 .9% in members of high-risk groups depending on the cutoff used for positive reactivity and the incidence of HIV infection (112) . While the EIA kits are very sensitive compared with the Western blot, it should be remembered that these assays detect antibody to HIV, not antigen. Therefore, HIV-infected individuals may be missed by antibody tests prior to seroconversion. Seroconversion usually occurs within 2 to 3 months (35, 39, 45, 60, 72, 80) but can take up to 5 months (118) or even longer if the individual is immunocompromised (3) . One recent study reports that latent HIV infection may occur for up to 34 months or longer without overt seroconversion as detected by EIA screening tests (100) . Moreover, some EIA and Western blot methods detect only IgG antibody to HIV. Therefore, some current screening and supplemental Western blot assays will not detect HIV-infected individuals prior to the switch from IgM to IgG antibody (10, 93) . The time to switch from IgM to IgG HIV antibody has been reported to take as long as 41 weeks (9, 10) . Therefore, follow-up testing of individuals at high risk for HIV infection is important. In addition, it should be noted that current ETAs detect antibody to the predominant HIV strain. These tests were positive in only 5 (24%) of 21 patients infected with HIV-2 (34). Fortunately, no HIV-2 infections in blood donors or patients have been reported in the United States.
On the other hand, false-positive ETAs can occur. In general, false-positive results are inversely related to the degree of HIV EIA reactivity. In a blood bank screening program, highly reactive specimens by EIA were strongly associated with a positive Western blot or culture (86.7%), in contrast to moderately and weakly reactive specimens (1.9%) (124) . These false-positive results can be due to intrinsic variability in test performance, heat inactivation of serum, HLA antibodies with specificity for HLA DQ3 and DR4 antigens (found in the H-9 cell line used to grow stock virus), and probably other contaminating antigens from cell lines (12, 71) . False-positive EIA results have been reported to be as high as 19% in hemophilia patients (113) , 13% in alcoholic patients with hepatitis (83), 4% in hemodialysis patients (96) , and 24% in patients who have a positive rapid plasma reagin test (41) . Therefore, confirmatory testing of all EIA repeatedly reactive specimens is essential.
In addition to the commercial EIA kits which detect a number of different HIV antibodies, nonlicensed competitive ETAs (Abbott Laboratories, North Chicago, TIl.) which are specific for the detection of antibody to the core antigens or the envelope antigens have been developed (53) . These assays have beads coated with recombinant core antigen or with recombinant envelope antigen. Serum samples are incubated with the beads and enzyme-conjugated human antibody to HIV core or envelope antigen for 16 to 22 hs. Beads are washed and substrate is added. The intensity of the color formed is inversely related to the amount of antibody to the HIV core or envelope antigen in the sample. Antibodies to envelope antigens are most consistently found in patients with HIV infection, whereas p24 antibody titers appear to decline as HIV-infected individuals clinically deteriorate (6, 18, 53, 75, 76) . Declining p24 antibody titers therefore may have prognostic significance (125 (15) . In high-risk groups, on the other hand, the falsenegative rate is probably significantly higher. A reduction in false-negative and false-positive Western blots may be possible with the recent development of recombinant HIV antigens for use in immunoblotting due to the purity of these antigens.
IFA
The indirect IFA for HIV antibody is a fast and reliable supplemental test (13, 46, 64, 77, 92, 98, 106 11 (0.27%) of 4,000 gave nonspecific reactions that could not be removed by cell absorption. All 11 specimens were Western blot negative and 6 possessed antinuclear antibody.
The above results suggest that, compared with the Western blot, the TFA is equally sensitive and specific as a supplemental test. The IFA also has the advantage over Western blot of being performed in <2 hs; it also requires less technical expertise and can be run on either serum or plasma specimens. Moreover, since nearly all HIV-infected individuals have antibodies to the cell-associated proteins pgl60 and pgl20, the IFA will more readily detect these antibodies. gpl60 and gpl20 are expressed in infected cells, but are generally not present in purified preparations of virus used in EIA kits and in some Western blot procedures (37) . However, interpretation of the IFA is more subjective, and uninfected cells may be required for serum absorption.
RIPA
The RIPA is primarily a research technique in which HIV-infected cells in their peak log phase of growth are VOL. 1, 1988 exposed to radioactive isotopes (e.g., [35S]methionine) for a few hours, lysed with RIPA buffer, and then ultracentrifuged to obtain a soluble cell lysate containing radiolabeled viral proteins (2, 6-8, 38, 65, 67, 109) . Cell lysates are cleared first with negative control serum bound to protein A-Sepharose beads and then reacted with patient serum preabsorbed with protein A-Sepharose beads. The immunoprecipitates are eluted in sample buffer by boiling at 100'C and then separated by electrophoresis on sodium dodecyl sulfate-polyacrylamide gels. The banding patterns are similar to those of Western blot except that the gp120 and gp160 proteins are more often apparent by RIPA, whereas gp4l and core proteins are detected more effectively by Western blot (32, 45) . In addition, RIPA appears to result in fewer false positives in low-risk blood donors who have isolated bands to core proteins by Western blot (32, 45) . Therefore, RIPA is probably slightly more sensitive and specific than Western blot and should be considered as a possible supplemental test for serum samples that are indeterminate by Western blot or IFA (32, 37) . However, RIPA is mainly confined to the research laboratory because it is cumbersome and expensive and requires the maintenance of infected cell lines and handling of radioisotopes. (16) . The sensitivity and specificity of another EIA that uses a 12-amino acid gp4l peptide were reported to be 99.2 and 100%, respectively (51) . A dot enzyme immunoassay, using a recombinant envelope protein (sensitivity, 98.2%) and taking about 30 min to perform, has been developed (20) . A sensitive assay for the detection of HIV antibodies in saliva has also recently been reported (94 * Outreach programs for IV-drug abusers should be undertaken to increase their knowledge of AIDS and of ways to prevent HIV infection, to encourage them to obtain counseling and testing for HIV antibody, and to persuade them to be treated for substance abuse.
3. Persons who consider themselves at risk. All persons who consider themselves at risk for HIV infection should be counseled and offered testing for HIV antibody.
4. Women of childbearing age. All women of childbearing age with identifiable risks for HIV infection should be routinely counseled and tested for HIV antibody, regardless of the health-care setting. Each encounter between a health-care provider and a woman at risk and/or her sexual partners is an opportunity to reach them with information and education about AIDS and prevention of HIV infection. Women are at risk for HIV infection if they:
* Have used IV drugs. * Have engaged in prostitution. * Have had sexual partners who are infected or are at risk for infection because they are bisexual or are IV-drug abusers or hemophiliacs.
* Are living in communities or were born in countries where there is a known or suspected high prevalence of infection among women.
* Received a transfusion before blood was being screened for HIV antibody but after HIV infection occurred in the United States (e.g., between 1978-1985 [26] ). Educating and testing these women before they become pregnant allows them to avoid pregnancy and subsequent intrauterine perinatal infection of their infants (30-50% of the infants born to HIV-infected women will also be infected).
All pregnant women at risk for HIV infection should be routinely counseled and tested for HIV antibody. Identifying pregnant women with HIV infection as early in pregnancy as possible is important for ensuring appropriate medical care for these women; for planning medical care for their infants; and for providing counseling on family planning, future pregnancies, and the risk of sexual transmission of HIV to others.
All women who seek family planning services and who are at risk for HIV infection should be routinely counseled about AIDS and HIV infection and tested for HIV antibody. Decisions about the need for counseling and testing programs in a community should be based on the best available estimates of the prevalence of HIV infection and the demographic variables of infection. (52) . The principle of HIV antigen detection in these kits involves incubating the patient's specimen overnight with a polystyrene bead or in a plastic microwell coated with polyclonal anti-HIV antibody (Fig. 2) . The bead or microwell is then rinsed and incubated with a rabbit or goat antibody to HIV antigen to form a sandwich. After the bead or microwell is washed, an enzyme-conjugated anti-goat or anti-rabbit antibody can then be added to increase the test sensitivity and specificity. After a final wash, the appropriate substrate can be added. If the antigen-antibodyenzyme complex is present, a color change will be detected by an increase in absorbance at a specific wavelength. Dilutions of known amounts of HIV antigen can be used to generate a standard curve for quantitating the amount of free HIV antigen in the patient's specimen. The detectable limit for this assay is between 50 and 100 pg/ml (52, 53) .
If a specimen is found to be repeatedly reactive, a specific antibody neutralization assay should be performed to confirm the presence of HIV antigen. This assay is also com (66) . Likewise, the CSF of five of nine adults with AIDS-related encephalopathy and five of five children with AIDS had detectable HIV antigen (52). However, none was detected in the CSF of 13 symptomless HIV antibody-positive controls. The specificity is much better than the sensitivity. In testing serum of blood donors, 9 of 2,096 (0.43%) were repeatedly reactive but none of their specimens could be neutralized, indicating false-positive reactions (115 AIDS, 1987) . Such patients could be selected for clinical trials, using drugs active against HIV such as zidovudine (formerly known as azidothymidine).
(iii) HIV-infected patients receiving antiviral drug therapy. Mean HIV antigen levels have been shown to decrease significantly over time in patients treated with zidovudine compared with placebo-treated controls (31) . Monitoring of HIV antigen levels may be useful in measuring the antiviral effect of drug therapy.
(iv) HIV antibody-positive infants. HIV antibody may be passively transferred in utero from HIV-infected mothers without HIV transmission to the infant. A positive HIV antigen test on the infant's serum is useful in confirming HIV infection (86) .
(v) Differentiating AIDS from primary immunodeficiency syndromes in HIV antibody-negative children. Since antibody response may be blunted or absent in children with congenital immunodeficiency syndromes, the diagnosis of AIDS may be missed if only HIV antibody testing is performed (14) . HIV antibody-negative children with an immunodeficiency syndrome should be checked for HIV antigen, especially if they received a transfusion prior to antibody testing or the mother is HIV antibody positive.
(vi) Individuals with indeterminate supplemental antibody tests. Most healthy individuals in low-risk groups with indeterminate Western blots are probably not infected (120), but a negative antigen test may provide some reassurance, especially if the Western blot or RIPA indicates the absence of antibodies to p24/55.
HIV CULTURE
In 1983, HIV was first propagated by using phytohemagglutinin (PHA) and T-cell growth factor in cocultures of lymph node cells from a homosexual with lymphadenopathy and T lymphocytes from a healthy adult donor and from umbilical cord blood of newborn humans (7) . The presence of HIV was detected by electron microscopy, showing lymphocytes with characteristic immature particles with dense (C-type) budding at the plasma membrane, and high levels of reverse transcriptase (RT) activity in the culture supernatant fluid on day 15 of coculture.
Subsequently, Gallo et al. confirmed these findings and developed a cell culture system, using clones (H4, H9) of a neoplastic T-cell line (HT) for the continuous production of HIV (47, 98) . The presence of HIV was further confirmed by serological analysis (107, 109) and by IFA, using fixed cells of HT-infected clones and rabbit antiserum to HIV or patient serum (98).
Levy and Shimabukuro reported the recovery of HIV by RT assay to be about 68% (53 of 78) in AIDS patients, 41% (7 of 17) in HIV antibody-positive asymptomatic homosexual males, and 0% (0 of 85) in antibody-negative healthy heterosexuals, using cocultures of patient peripheral mononuclear cells (PMC) and PHA-stimulated human PMC from clinically healthy individuals (78) . In 64% of the positive cultures, RT activity was detected within 9 to 15 days from initiation of culture and in an additional 21% after 21 days. From a diagnostic viewpoint these results were rather discouraging, because the sensitivity of culture is relatively poor, the time to positivity is relatively long, the RT assay is tedious, and the cost of reagents and labor is several hundred dollars. Moreover, RT AIDS patients, 32 of 33 (97%) HIV antibody-positive asymptomatic homosexual males, 14 of 14 (100%) HIV antibodypositive symptomatic hemophiliacs, and in 0 of 18 HIV antibody-negative hemophiliacs. In terms of time to positivity, HIV antigen was detected in 46% of positive culture supernatant fluids by day 3 of culture, in 94% by day 10, and in 100% by day 21. We are now testing these patients' sera for HIV antigen.
In our laboratory, it appears that HIV can replicate more quickly and consistently in mitogen-stimulated donor PMC than in cell lines. However, it is necessary to refeed the culture every week or two with freshly stimulated PMC to sustain HIV replication.
In addition, the HIV antigen EIA has the following advantages over the RT assay for detection of HIV in culture. However, the RT assay has the theoretical advantage of detecting other HIV strains (HIV-2) or other retroviruses that the current HIV antigen EIAs may miss (33, 97) . There are a number of published RT assay procedures for those laboratories interested in detecting RT activity in concen-trated culture supernatant fluid (5, 63, 78, 97, 103) . The principle of most of these RT assays is as follows.
RT is an enzyme unique to a group of viruses known as retroviruses, of which the HIV is a member. RT is a ribonucleic acid (RNA)-dependent DNA polymerase encoded for by the poi gene and requires Mg2". In the RT assay, an RNA template primer, polyriboadenylate:
oligodeoxythymidylate12-18 (a long adenine strand as the template and a short thymidine strand as the primer), is mixed with radioactive tritium, [3H]thymidine, a buffer containing Mg2+, dithiothreitol as a reductant, Triton X-100 as a detergent to disrupt whole virus particles, and a sample of concentrated culture supernatant. This mixture is incubated at 370C for 1 h. If RT is present in the sample, the radioactive thymidine will be incorporated onto the template. Cold acid is added to stop the reaction and precipitate the strands. After an incubation on ice, the reaction mixture is poured over a filter to trap the strands and washed to remove unbound [3H]thymidine. The filters are put into scintillation vials, dried, and counted in scintillation cocktail. Activity (in counts per minute) over a certain limit is indicative of HIV presence in the sample. To detect contaminating cellular DNA polymerases which could result in a false positive, the RT assay is run simultaneously, using a DNA template primer, polydeoxyadenylate:oligodeoxythymidylate12-18, instead of the RNA template primer.
The clinical utility of isolating HIV from the peripheral mononuclear cells of different patient groups is similar to that of the serum HIV antigen assay (see above). However, culture is more sensitive. In addition, one study reported a strong association between clinical status and the rate of replication of HIV isolates in vitro, suggesting that culture may be useful for determining strain virulence (5). Moreover, time to positivity in culture may correlate with the patient's viral load since it has been shown to increase from 7 to 22 days with a 1i-' dilution of stock virus (102) . HIV culture may also be useful in monitoring drug therapy. The authors of one study reported a significant drop in their ability to isolate HIV from mhononuclear cells in patients receiving an antiviral drug called ampligen (21) .
The drawbacks to HIV culture are that it is expensive, it may take weeks, and it creates the potential for exposure of personnel to high concentrations of virus.
HIV can also be cultured from other body fluids, including CSF (59), serum (85) , cervical secretions (121) , saliva (56, 58) , semen (61, 127) , plasma (40, 44) , tears (43) , breast milk (116) , and brain tissue (79) . However, the percentage of HIV recovery is less from these fluids: 73% in CSF from patients with AIDS-related neurologic syndromes (59), 4% in saliva of AIDS patients (58) , and 70% in the plasma of AIDS patients (40) . The Transmission of HIV infection by accidental inoculation with a needle contaminated with blood from an HIV antibody-positive patient has been documented by seroconversion in at least four health care workers with no other risk factors for HIV infection (4, 88, 90, 114) . More recently, three instances of health care workers who appeared to acquire HIV infections from skin or mucous membrane exposure to blood from HIV-infected patients have been reported (27) . Still, the risk of HIV transmission from needlesticks or mucous membrane exposure to HIV-infected blood appears to be low. In a CDC cooperative surveillance project, none of 82 health care workers who had open wounds or mucous membranes exposed to HIV-infected blood have seroconverted, and only 1 of 298 (0.3%) health care workers seroconverted after needlestick injuries or cuts with sharp objects contaminated with HIV-infected blood (82) . In contrast, the risk of acquiring hepatitis B virus infection following a needlestick from a hepatitis B virus carrier ranges from 6 to 30% (54, 110) .
In 1985, two different reagent production laboratories reported that several laboratory workers may have been inadvertently exposed to an aerosol of concentrated HIV; one worker was cut by a piece of glass from a broken carboy that contained HIV-infected cells and culture fluid. None of the potentially exposed persons had shown evidence of seroconversion after 6 months in one incident and 12 months in the other as a result of these occupational exposures (24) . A technologist in our laboratory who has handled over 500 positive cultures in the last 2 years has not seroconverted nor have the other four technologists and four nurses in our AIDS Treatment Evaluation Unit who voluntarily agree to be tested every 3 months for HIV antibody. However, officials at the National Institutes of Health recently reported that a person who worked in an HIV propagation laboratory became HIV antibody positive. This individual apparently had none of the known risk factors for contracting HIV, and accidental exposure was not reported (91) .
To minimize the risk of HIV transmission in the laboratory the following recommended precautions printed here from Morbidity and Mortality Weekly Report should be adhered to (24 Laboratory coats, gowns, or uniforms should be worn by laboratory workers, as is customary for other BSL 2 or 3 practices, depending on the nature of the work, concentration of the virus, and volume of material being handled. Because many animals bite, and some throw feces, urine, or expectorate at humans, animal-care personnel must wear coats, protective gloves, coveralls or uniforms, and face shields as appropriate to protect the skin and mucous membranes of the eyes, nose, and mouth from potential exposure to these substances when working with animals likely to manifest such behavior.
2. Activities such as growing research-laboratoryscale amounts of HIV or related viruses or virusproducing cell lines, working with concentrated virus preparations, or conducting procedures that may produce droplets or aerosols should be performed in a BSL 2 facility with the additional practices and containment equipment recommended for BSL 3.
3. Activities involving industrial-scale, large-volume, or high-concentration production and manipulation of HIV are to be conducted with BSL 3 requirements.
4. All laboratory glassware, equipment, disposable materials, and wastes suspected or known to contain HIV must be decontaminated, preferably in an autoclave, before washing, discarding, etc. Incineration of solid wastes may be used as an alternative method of disposal.
5. There is no evidence that laboratory clothing soiled with materials known or suspected to contain HIV poses a transmission hazard, and the handling of such clothing is covered under BSL 2 practices. However, to be consistent with BSL 3 recommendations, when laboratory clothing becomes contaminated with HIV preparations, it should be decontaminated before being laundered or discarded.
6. Work surfaces should be decontaminated at the end of each day on completion of procedures or when overtly contaminated. Many commonly used chemical disinfectants with such active ingredients as sodium hypochlorite, formaldehyde, glutaraldehyde, or phenols, can be used to decontaminate laboratory work surfaces; they can also be used to decontaminate some laboratory instruments, specific areas of contaminated laboratory clothing, and spills of infectious materials. Prompt decontamination of spills and other overt contamination should be standard practice.
7. The prudent and recommended approach to handling human serum known or suspected to contain HIV is to use the same precautions that should be used routinely to prevent transmission of blood borne infections, including hepatitis B. Available data on the effectiveness of heat to destroy HIV suspected or known to be present in human serum are at variance because of variations in volume of serum, concentration of the virus, temperature, and duration of exposure to heat. Similarly, results of chemical analyses or antibody assays may vary when sera are heated before testing according to the analysis or assay being performed. However, there is agreement that testing heated serum for HIV antibody by enzyme immunoassays often yields false-positive results.
8. No HIV vaccine has been developed, and no drugs have been shown to be completely safe and effective for therapy. As part of an ongoing medical surveillance program for employees, all laboratory workers before being assigned to activities with a high potential for exposure should have a serum sample obtained and stored at -40TC (-40'F) for possible future testing.
Subsequent serum samples should be obtained and stored in accordance with laboratory policy or following an inadvertent laboratory exposure involving materials described above. When indicated, these serum specimens should be tested by a qualified laboratory using currently recommended procedures for HIV antibody. Furthermore, the physician requesting serologic testing of these serum specimens must first obtain informed consent from the laboratory worker and describe the confidentiality safeguards available to protect test results. The laboratory workers whose serum specimens are to be tested should understand how the test results are to be used, the implications of a positive or negative test result, and the limits, if any, of the confidentiality safeguards. An employee whose serum HIV antibody test is reactive and whose subsequent test and evaluation confirm the presence of HIV infection should be counseled to follow the Public Health Service recommendations for preventing transmission.
9. In addition to HIV, other primary, as well as opportunistic, pathogenic agents may be present in the body fluids and tissues of persons who are antibody positive or have AIDS-related complex or AIDS. Laboratory workers should follow accepted bio-safety practices to ensure maximum protection against inadvertent laboratory infection with agents other than HIV that may also be present in clinical specimens. 
Addendum

